Amy Miller
Amy Miller, executive VP of the Personalized Medicine Coalition, will join the Society for Women's Health Research as its new CEO starting Jan. 3, 2017. At PMC, Miller worked with stakeholders accross academia, industry, and governement to support policies that would spur development and adoption of diagnostics and peronalized drugs that capitalize on biological differences among individuals. Previously, at the office of the Director of the National Institute of Mental Health, Miller worked to connect researchers, legislators, patients, and their families. She was also a fellow at the American Association for the Advancement of Science and domestic policy advisor to Senator Jay Rockefeller.
Daniel J. Warmenhoven
Theranos has appointed Daniel J. Warmenhoven to its board of directors, effective immediately. Warmenhoven has served in various positions with many companies in the technology industry, including as CEO of NetApp and as executive chairman of the NetApp board of directors. He has also served as chairman, president, and CEO of Network Equipment Technologies, and has held senior management positions at Hewlett-Packard and IBM. He is currently a director on the boards of Bechtel Group and Palo Alto Networks. Warmenhoven is replacing retiring director Riley P. Bechtel, who is stepping down because of health issues.
Theranos also announced that it will retire its Board of Counselors as part of an ongoing restructuring of its corporate advisory framework.
Maria Chan
Personal Genome Diagnostics has appointed Maria Chan vice president of regulatory strategy. Chan will oversee all regulatory activities at PGDx and will help shape the company's strategy for moving products through regulatory processes. Chan previously served as director of the Division of Immunology & Hematology Devices at the Center for Devices & Radiological Health, in the US Food and Drug Administration's Office of In Vitro Diagnostics & Radiological Health. She also served as a scientific reviewer and team leader of immunology, genetics, and molecular diagnostic devices, and as associate division director for the immunology branch at the FDA. Prior to the FDA, Chan served in various positions at Children's National Health System, the George Washington University Medical Center, and the Johns Hopkins University School of Medicine.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.